SAB BIOTHERAPEUTICS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $13.3M | $-34.1M | $-42.2M | $-18.7M | $-17.1M | $20.1M |
| Depreciation & Amortization | $3.0M | $4.7M | $3.7M | $3.2M | $1.5M | $383.1K |
| Depreciation | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $5.2M | $2.9M | $2.4M | $2.7M | $2.3M | $1.3M |
| Net Cash from Operating Activities | $-44.8M | $-34.3M | $-25.1M | $-23.5M | $2.0M | $10.0M |
| Investing Activities | ||||||
| Capital Expenditures | $933.2K | $337.3K | $197.2K | $2.2M | $10.9M | $12.7M |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-121.7M | $-12.0M | $-152.7K | $-2.1M | $-10.9M | $-12.7M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $168.3M | $-1.2M | $66.8M | $1.1M | $35.9M | $9.0M |
| Net Change in Cash | $1.6M | $-47.7M | $41.5M | $-24.5M | $26.9M | $6.3M |
| Free Cash Flow | $-45.7M | $-34.6M | $-25.3M | $-25.6M | $-9.0M | $-2.7M |